Background: The Asthma Impact on Quality of Life Scale (A-IQOLS) assesses the patient-perceived negative effect of asthma on quality of life. Its standard error of measurement is known; it has strong construct, convergent, and divergent validity; and it provides information that is unique among asthma outcome measures. Objective: We sought to characterize the psychometric properties of the A-IQOLS and its suitability for use in demographically and clinically diverse adult asthmatic populations. Methods: Data from participants in 5 independent asthma studies, with samples ranging from patients with well-controlled moderate asthma to patients with severe poorly controlled asthma, were pooled to determine the psychometric performance of A-IQOLS scores overall and in multiple demographic, disease status, and study subgroups. Results: Pooled sample (n 5 597) age averaged 45 years; 66% were female, 65% were white, 22% were African American, 11% were Hispanic, and 11% had a high school education or less. The rated importance of its underlying life dimensions and associations between A-IQOLS scores and lung function, symptom, Asthma Control Test, Juniper Mini Asthma Quality
Standardized core outcome measures used in asthma research include spirometry, asthma control, exacerbations, and health care use. 1 No measure of a patient's asthma-related physical, social, emotional, or role functions or quality of life (QoL) has been recommended as a core outcome. Recently, a measure is available that assesses the patient's perspective on the effect of asthma and its treatment on QoL.
The Asthma Impact on Quality of Life Scale (A-IQOLS) asks patients to rate the negative effect of their asthma on each of 16 research-based dimensions of QoL on a 5-point scale.
2 A-IQOLS summary scores (the average of the dimension ratings) are interpretable on the original rating scale. In the Asthma Quality of Life Impact Study (AQOLIS)'s test-retest study, A-IQOLS has strong content, convergent, and divergent validity, and its SEM was determined to be 60. 27 . Participants in AQOLIS had diverse levels of asthma severity, a wide range in level of asthma control, and moderate racial and ethnic diversity. However, its size (n 5 147) and composition did not support subgroup analyses to determine the generalizability of the A-IQOLS's psychometric properties to specific patient populations, such as those with low education, from specific racial/ethnic backgrounds, or with severe asthma.
In addition, A-IQOLS was administered as an ancillary measure in 4 additional independent asthma clinical trials that differed widely in target population, eligibility criteria, clinical intervention, and study design. Pooled baseline data from all 5 studies were analyzed to (1) determine whether the rated personal importance of the Flanagan Quality of Life Scale dimensions and psychometric performance of the A-IQOLS support its use in diverse demographic groups and clinical populations, (2) evaluate the A-IQOLS's sensitivity for differences in asthma severity and clinical
Studies
The following studies contributed baseline data for pooled analysis: The eligibility criteria of LASST, AQOLIS, and BTR (see Table E1 in this article's Online Repository at www.jacionline.org) ensured that enrolled patients had persistent asthma and were prescribed asthma treatment at or greater than step 2.
7 Asthma in LASST patients was well controlled and relatively stable on combination inhaled corticosteroids and long-acting b-agonists (step 4 treatment). AQOLIS participants had persistent asthma (treatment steps 2-6), without regard to level of asthma control. 2 The DASH study targeted obese patients with poorly controlled asthma, and the CPAP study targeted patients with stable asthma and airway reactivity without regard to treatment step. BTR participants had severe asthma, which was defined as asthma that was uncontrolled despite high-dose inhaled corticosteroids plus long-acting b-agonists and/or other asthma controller medications (ie, step 5 or 6 antiasthma treatment), and were approved to undergo bronchial thermoplasty.
Data
Baseline data were available for 597 patients (AQOLIS, n 5 152; LASST, n 5 227; CPAP study, n 5 92; and BTR, n 5 38).
Treatment step. Pharmacotherapy regimens were documented in all but the CPAP study and were classified by step per US treatment guidelines. 7 Lung function. Baseline lung function was assessed before and after bronchodilator use by using American Thoracic Society-recommended procedures and equipment. 8 Race-specific norms were used to determine percent predicted FEV 1 (PPFEV 1 ) values.
Asthma control. All studies administered the Asthma Control Test (ACT). Symptoms. The Asthma Symptom Utility Index (ASUI) 10 was administered in LASST, the CPAP study, and AQOLIS. Juniper Mini-Asthma Quality of Life (Mini-AQLQ) symptom subscale 11 scores were available for AQOLIS, the DASH study, and BTR.
Disease-specific health status. Asthma symptoms and impairment in patients' physical, social, emotional, and/or role functions were assessed based on the Mini-AQLQ score 11 in AQOLIS, the DASH study, and the CPAP study; the Juniper standardized AQLQ in BTR; and the Marks 25 . For LASST, the CPAP study, and BTR, age at enrollment was available to the nearest tenth of a year. The patients' pharmacotherapy regimens were documented in all except the CPAP study. àIn the CPAP study lung function was measured 0 to 2 weeks before the baseline questionnaire was administered. One AQOLIS, 2 DASH study, and 5 BTR participants were missing a lung function value. §In the DASH study the ACT was used for telephone eligibility screening. kAfter controlling for age, sex, race, ethnicity, and education, the overall test of group ACT score differences remained significant (P < .0001), as did all pairwise study comparisons (all P < .0001). Pooled sample size in these analyses was 593. The resultant least-square ACT score means (LASST, 23.0; AQOLIS, 18.7; CPAP study, 20.9; DASH study, 14.9; and BTR, 10.5) were virtually the same as the unadjusted means. {Pearson correlation between ASUI and Mini-AQLQ symptom scores in the AQOLIS sample was 0.81. Linear regression was used to impute ASUI scores from Juniper symptom scores in the DASH study and BTR samples and to impute Mini-AQLQ symptom scores in the LASST sample and CPAP study samples from their ASUI scores. #BTR used the full-length standardized Juniper AQLQ questionnaire. **Pearson correlation between the Mini-AQLQ total score and the Marks AQLQ score in the AQOLIS sample was 20.80. Linear regression was used to impute Marks AQLQ scores for DASH study and BTR samples from their Juniper total scores and to impute Juniper total scores in the LASST and CPAP studies from their Marks scores.
One CPAP study participant was missing a Marks AQLQ score. ààA subject's standard A-IQOLS summary score was defined as S 5 + n d 5 1 r d n , where r d is their rating of the effect of asthma on dimension d, and n is the number of dimensions rated, typically 16. § §After controlling for age, sex, race, ethnicity, and education, the P value was less than .0001. After further controlling for ACT score, the P value was less than .0001; least-square means for A-IQOLS scores were as follows: LASST, 1.4; AQOLIS, 1.3; CPAP study, 1.5; DASH study, 1.3; and BTR, 2.2. All pairwise study comparisons with BTR were significant (P < .0001). Other pairwise study comparisons were not significant. Asthma Quality of Life Questionnaire (Marks AQLQ) 12 in AQOLIS, LASST, and the CPAP study.
A-IQOLS. A-IQOLS
2 was self-administered by patients, requiring less than 5 minutes (typically 3-4 minutes). It asks the following: ''Over the past four weeks, how much did your asthma negatively affect your life in each of the following areas?'' Respondents were instructed to ''Consider the effects of the asthma itself, the asthma medications you use, and anything you did to avoid, treat, or get medical care for asthma symptoms.'' Ratings were obtained on each of 16 life dimensions 13,14 on a 5-point, unidirectional, Likert-type scale: 1, no negative effect at all; 2, slightly negative effect; 3, moderately negative effect; 4, very negative effect; and 5, extremely negative effect.
One study (AQOLIS) added the following question assessing the overall effects of asthma: ''In the past four weeks, how much did your asthma negatively affect your life overall'' at both test and retest assessments? Responses used A-IQOLS' 5-point negative effect rating scale.
Flanagan Quality of Life Scale dimension importance questionnaire. The personal importance of each of the Flanagan Quality of Life Scale dimensions 13 plus the Burckhardt addition of independence was determined in all 5 asthma studies. Respondents were asked the following: ''At this time in your life, how important is each of the following areas to you?'' Ratings were obtained on a 5-point scale: 1, not at all important; 2, only slightly important; 3, moderately important; 4, important; and 5, very important. The importance questionnaire has no summary score.
Statistical analysis
Sample characteristics. Means 6 SDs or proportions, as appropriate, were calculated for patients' characteristics for the pooled sample, each constituent study, and the demographic subgroups defined by age, sex, race, ethnicity, education, and ACT score category. Subgroup differences were evaluated by using t tests and linear regression methods.
QoL dimension importance. The mean (SD) rated importance
of each QoL dimension, and the proportion of patients rating each dimension as important/very important was determined for the pooled sample and demographic subgroups.
Asthma outcome measure scoring. All standardized asthma outcome measures were scored and scaled by using their published algorithms: ACT, 9 ASUI, 15 Marks AQLQ, 16 Juniper AQLQ, 11, 17, 18 and A-IQOLS.
2
The A-IQOLS summary score is shown as follows: S 5
n , where r d is the subject's asthma negative effect rating for each dimension (d) and the number of dimensions actually rated (n).
2 Dimension importance ratings do not have to be obtained to score the A-IQOLS. Importance weighted and unweighted A-IQOLS scores were highly correlated (r 5 0.99) and had similar correlations with other asthma outcome measures.
Convergent and divergent validity. Pearson correlations
between A-IQOLS summary scores and other asthma outcome measures were determined for the pooled sample and demographic subgroups. The strength of the correlations (r) was interpreted as follows: very weak, 0.00 to 0.19; weak, 0.20 to 0.39; moderate, 0.40 to 0.59; strong, 0.60 to 0.79; and very strong, 0.80 to 1.0. 19 The R 2 value estimates the proportion of common variance between any 2 measures.
Internal consistency reliability. The standardized coefficient a was calculated to characterize the internal consistency of the A-IQOLS dimension ratings.
Sensitivity to differences in asthma status. An overall test of difference among the 5 studies on each asthma outcome was performed, as were various pairwise comparisons. No specific study differences were hypothesized, and hence no adjustment was made for multiple pairwise comparisons.
Association between change in overall asthma effect rating and change in A-IQOLS score. Linear regression and descriptive analyses were used to estimate the size of the change in A-IQOLS score associated with a 1-category change in the rated overall negative effect of asthma in the AQOLIS sample.
Estimation of the minimum clinically important difference. The minimum clinically important difference (MID) is the smallest change in a score that patients perceive as beneficial (or detrimental) that would mandate, in the absence of other considerations (eg, side effects and excessive cost), a change in the patient's management. 20 The MID defines cut points in change scores that distinguish between improvement, stability, and worsening. The definition of the MID presumes that the difference is large enough to be a true difference but not the result of measurement error.
A triangulation approach, as recommended by Leidy et al 21 was used to estimate the MID of the A-IQOLS from the following: (1) distribution-based considerations 22 ,23 using Wyrwich et al's suggested value of 1 SEM, 24 McHorney and Tarlov's suggested value of 1.96 SEM, 25 and intermediate values that represent the smallest score changes that constitute a true difference with 80% and 67% probability (1.81 and 1.15 SEM, respectively), and one half the measure's SD 26 and (2) an anchor-based estimation approach determining the magnitude of the A-IQOLS score change that was associated, by using linear regression, with a 1-category change in the patient's rating of the overall negative effect of asthma between test and retest in AQOLIS.
All statistical analyses were performed with SAS software (version 9.2; SAS Institute, Cary, NC). A significance level of .05 was used throughout.
RESULTS

Sample demographic characteristics
Mean age of participants was approximately 45 6 14 years; 66% were female 65% were white, 22% were black, 9% were Asian, 4% were another race, and 11% were Hispanic (Table I) . Approximately 11% had a high school education or less, 36% had some college, and 53% had a 4-year college or advanced degree.
As expected based on eligibility criteria, the 5 studies had diverse asthma outcome status (P <.0001, Table I ) and constituted a very heterogeneous population of patients with persistent asthma. Demographically, they differed in age, education level, and race but not sex or ethnicity. BTR patients, who all had severe refractory asthma, had significantly worse lung function (PPFEV 1 ) than the other samples, which was similar to values reported for adult patients categorized as exacerbation prone in the Severe Asthma Research Program 3 severe asthma cohort. 27 BTR patients also had higher symptom levels (ASUI and Juniper AQLQ Symptom scores), worse asthma control (ACT scores), greater impairment in functional status (Mini-AQLQ total and Marks AQLQ scores), and higher A-IQOLS scores (greater negative effect) compared with the other 4 studies (Table II and see Fig  E1 in this article's Online Repository at www.jacionline. org). Conversely, LASST patients, who were selected for good asthma control, had better status on all asthma measures than patients from the other 4 studies. Results for the combined AQOLIS and CPAP samples are also presented (Table II) because they are the most similar samples, and results for this composite might be useful for planning future studies with similar eligibility requirements.
The AQOLIS, CPAP study, and DASH study samples fell between the LASST and BTR samples on all 7 asthma outcomes (see Fig E1) . Of the 3, the DASH study was the most distinct, with numerically but not necessarily significantly worse status on all asthma outcome measures, except symptoms. The AQOLIS and CPAP study samples varied in their positions relative to the DASH study sample, depending on which asthma outcome measure was considered. A-IQOLS scores differed significantly between the AQOLIS and DASH study samples and between the combined AQOLIS/CPAP study and DASH study samples, but ASUI, Mini-AQLQ total and symptom, and Marks AQLQ scores did not. By contrast, ASUI and Mini-AQLQ symptom scores differed significantly between the CPAP study sample and both the DASH study and AQOLIS, whereas Mini-AQLQ total, Marks AQLQ, and A-IQOLS scores did not.
Perceived importance of QoL dimensions
From 60% to 97% of patients in the pooled sample rated 15 of the individual QoL dimensions as personally important/very important, and 56% rated 12 or more of the 16 dimensions as personally important/very important (Fig 1, A) . Only dimension 8, "Participation in activities relating to local and national government and public affairs," was considered important/very important by fewer than half of the patients (23%). No importance ratings were missing.
The dimension importance patterns were very similar for men and women and patients of all ages, races, ethnicities, and education levels (see Fig E2 in this article's Online Repository at www.jacionline.org), with the exception that younger subjects on average considered "Having and raising children" (dimension 4) to be less important than older subjects.
Despite similar mean importance rating patterns across demographic subgroups, there was substantial individual variability. To characterize this, the absolute difference between each subject's importance rating on a given dimension and the dimension's overall mean importance rating was calculated and summed across the 16 dimensions. The mean of the individual deviations was 12.8 (SD, 3.7). Subjects' summed differences ranged from 4.9 (a subject with importance ratings similar to the sample average ratings) to 35.0 (a subject with a > _2-point average deviation from the sample mean dimension importance ratings). Demographic characteristics together accounted for only 2% of the variance in deviations; 98% was due to other (undetermined) individual differences and measurement errors. Only increasing age was significantly associated with greater deviation (P 5 .03).
Negative effect of asthma: A-IQOLS summary scores
A-IQOLS scores and dimension ratings. Missing A-IQOLS ratings were rare: only 3 of 597 patients omitted 1 and only 1 patient omitted 2 dimension-negative effect ratings.
In the pooled sample and the individual study samples, the dimensions of "Health/safety" and "Active recreation" were most negatively affected by the patient's asthma and its treatment, with "Work," "Material well-being," "Independence," and "Socializing" somewhat more negatively affected than the remaining 10 dimensions (Fig 1, B) . BTR (severe asthma) patients reported substantially greater negative effects on all QoL dimensions than those of the other study samples, and greater negative effects on the "Work," "Socializing," "Health/safety," and "Active recreation dimensions" relative to the other 10 dimension than the other studies. There was substantial individual variation in the dimensions perceived to be most negatively affected by their asthma (eg, 59.1% of patients considered the negative effect to be as great or greater on > _1 of the other dimensions than on any of the 6 most commonly affected dimensions).
Demographic subgroup A-IQOLS score comparisons. A-IQOLS scores did not differ significantly as a function of age, sex, race, or ethnicity (see Table E2 in this article's Online Repository at www.jacionline.org) but differed significantly by level of education (ie, greater negative effect of asthma in those with high school education or less) and treatment step (greater negative effect at higher treatment step). These associations (P 5.02 and P < .0001, respectively) persisted after controlling for ACT score (P 5.008 and P 5 <.0001). Thus the greater perceived negative effects of asthma and its treatment among patients with more intense treatment regimens, lower education, or both are not explained by subgroup differences in level of disease control but might be due to their functional impairments or the cost, inconvenience, or side effects of asthma treatment.
Correlations between A-IQOLS scores and other outcomes (convergent and divergent validity)
A-IQOLS scores were significantly correlated with all other asthma outcome measures (Table III) . Although statistically Values in boldface indicate statistical significance. *Study sample size: LASST, n 5 227; AQOLIS, n 5 152; CPAP study, n 5 92; DASH study, n 5 88; and BTR, n 5 38. One AQOLIS, 2 DASH study, and 5 BTR participants were missing a lung function value. àASUI scores imputed from Mini-AQLQ symptom scores for DASH study and BTR samples. §Mini-AQLQ symptom scores were imputed from ASUI scores for LASST and CPAP study samples. kMini-AQLQ total scores were imputed from Marks AQLQ scores for LASST and CPAP study samples. {Marks AQLQ score is missing for 1 CPAP study participant. #Marks AQLQ scores were imputed from Juniper total scores for DASH study and BTR samples.
**A subject's standard A-IQOLS summary score was defined as S 5 + J ALLERGY CLIN IMMUNOL VOLUME 143, NUMBER 1 significant, the correlation between PPFEV 1 and A-IQOLS score was very weak (r 5 20.13). For all other asthma outcomes, the correlations were highly significant (P < .0001) but ranged from very weak (ASUI) to moderate (ACT and Marks AQLQ) and strong (Mini-AQLQ). In all cases the shared/common variance (R 2 ) between the A-IQOLS score and the other asthma measures was 48% or less, confirming, as previously reported for the AQOLIS sample, 2 that the A-IQOLS provides substantial unique information not provided by the other measures.
In all age groups, male and female subjects, Hispanic and non-Hispanic subjects, all racial groups, and those at different levels of education, associations between A-IQOLS scores and other asthma outcome measures were statistically significant, and their absolute and relative magnitudes, as well as their R 2 values, were similar to those in the pooled sample as a whole (see Table E3 in this article's Online Repository at www.jacionline.org). The only exception was that the correlations between the A-IQOLS score and PPFEV 1 tended to be lower and not statistically significant in numerically smaller subgroups, which also tended to be less heterogeneous than the pooled sample as a whole on both measures.
Estimation of the MID. The SEM of the A-IQOLS score averaged across all score levels was determined previously to be 0.27.
2 One recommended estimate of the MID based on its distributional properties (ie, its SEM) is 61.96 SEM, 25 which yields an MID of 0.54 for A-IQOLS score. This criterion provides 95% probability that a change of this magnitude or greater is a true change (ie, statistically reliable). An alternative criterion (61 SEM) yields an estimated MID of 0.27 24 but less assurance that the change is real. Other levels of assurance can be considered as well. For example, the smallest A-IQOLS score change that constitutes a true change with 80% probability would be 61.81 SEM (MID 5 60.49) or, if only 67% probability was acceptable, 61.15 SEM (MID 5 60.31).
Another distributional approach to estimating the MID is to use one half the SD of the measure. The A-IQOLS score SD in the pooled sample (0.68; Table I ) yields an estimated MID of 0.34.
An anchor-based approach to estimating the MID uses self-reported change (eg, a patient's perception that the negative effects of asthma had increased, decreased, or remained the same) over a given time period. Reliance on a single item reporting perceived change has been criticized on methodologic grounds and might not provide new information because the results of many such studies turn out to yield an MID value close to one half the SD of the measure. 26 In AQOLIS, however, patients were asked for an overall rating of the negative effect of asthma on their life at both test and retest assessments, allowing direct determination of change rather than retrospective report. By using simple linear regression, a 1-category change in the patient's overall assessment was associated with a 0.23-point change in A-IQOLS summary score.
Considering these various estimates, it appears reasonable to consider the A-IQOLS score's MID conservatively to be approximately one half scale score point (0.50) and possibly somewhat less if one is willing to accept less assurance that the change exceeds statistical variability.
A-IQOLS' internal consistency reliability. The standardized coefficient a is reported commonly, even though it is not informative regarding measurement reliability. Standardized coefficient a values of A-IQOLS scores were high in the pooled sample as a whole (a 5 0.97) and in all demographic subgroups (a 5 0.94-0.98).
DISCUSSION
We evaluated the psychometric properties of the A-IQOLS in 5 asthma studies constituting a large heterogeneous population, representing multiple demographic subgroups and asthma severities. The dimensions underlying the A-IQOLS were personally important for substantial proportions of patients in all demographic subgroups. These findings reinforce the content and construct validity of the A-IQOLS score for use in diverse populations. Similar ratings of which dimensions are important, similar associations between A-IQOLS scores and other asthma outcome measures, and similar standardized coefficient a values in all subgroups suggest that patients, including those with low education, had a similar understanding of the dimension descriptions and rating task. A strength of the A-IQOLS is that subjects can characterize the negative effects of asthma in light of how important each dimension is to them. The similarity of the mean dimension importance ratings across sex, race, and ethnic subgroups shows the general relevance of the dimensions. However, the validity and utility of the A-IQOLS do not depend on whether a subject's priorities are similar to others' priorities or whether the subject's priorities remain stable over time.
The question posed to respondents by the A-IQOLS differs substantially from the questions posed in instruments conventionally referred to as asthma-related QoL measures. A number of A-IQOLS dimensions also are not represented by items in other instruments or in the item bank of a newer measure: the RAND-IAQL. 28 When choosing items to include in disease-specific QoL measures, it has been common practice to pretest a pool of items and eliminate those that relate to domains that are affected in smaller proportion of respondents, are less strongly correlated with other items, or both. 28, 29 This practice reduces instrument length and administration time and tends to increase internal consistency reliability. However, it can compromise content validity by narrowing the range of disease effects that are assessed. The modest shared variances between the A-IQOLS and the Juniper and Marks AQLQ measures are likely due to the smaller number of life dimensions assessed by the latter measures. The construct validity of the IQOLS template requires including all dimensions of life, and because the A-IQOLS administration time is already brief, there is no need to exclude dimensions less commonly affected.
BTR patients, all of whom had severe asthma refractory to intensive asthma pharmacotherapy and who had been approved to undergo bronchial thermoplasty, typically believed their asthma was having an effect between "slightly negative" and "moderately negative" on most dimensions and a very negative effect on their overall health and safety (A-IQOLS score mean 6 SD, 2.67 6 0.87). Patients with moderate persistent asthma that was stable and well controlled (LASST) typically believed their asthma had very little negative effect on their life (mean, 1.22; only slightly greater than ''no negative effect at all''). Those with asthma that was not well controlled (eg, DASH study patients) typically believed that its negative effect was about halfway between ''no negative effect at all'' and a ''slightly negative effect.'' The relatively low mean A-IQOLS scores of the DASH study patients might seem surprising because the functional consequences and risks of poorly controlled asthma can be important. However, A-IQOLS scores indicate that how much the patient believes asthma affects his or her life, which perspective might be influenced by their overall QoL or other circumstances. Other life problems might overshadow the effects of asthma. In all these groups, however, the situation of individual patients varies substantially. Scores of 3.25 or greater were observed in all study groups, and scores of 4.38 or greater were observed in BTR, the CPAP study, and LASST.
In summary, the A-IQOLS, which is based on a comprehensive set of empirically derived dimensions of QoL, accommodates variation in individual priorities, yields reliable information on how and how much asthma negatively affects patients' lives and is associated with other asthma outcomes but provides unique information, has a score range that makes it useful across the full spectrum of asthma severity and control, requires only a few minutes to administer, and is not copyrighted. The underlying IQOLS template (dimensions, stem question, and rating scale) can be easily modified for use in other diseases/conditions, assuming their psychometric performance, when evaluated, supports such use.
Measurement reliability and the MID
Lydick and Epstein
22 noted that any change in a QoL measure can be considered clinically significant in that it represents the patient's perception of an altered health outcome. However, this proposition needs to be tempered. The evidence presented here suggests that the minimum clinically important within-person change (MID) of the A-IQOLS score is approximately 0.50 but that somewhat smaller changes (between one third and one half a scale score point) might be informative, whereas smaller changes are more likely to be caused by measurement error. As with any new measure, it will take time and experience with its response to clinical interventions to clarify the clinical importance of within-person A-IQOLS score changes. 22 
Use of the results to inform sample size and power calculations
When planning studies in which the A-IQOLS might be a primary or secondary outcome measure, the information provided J ALLERGY CLIN IMMUNOL VOLUME 143, NUMBER 1 in Table I and Table E2 can be used to estimate sample size requirements or determine statistical power.
Limitations and future directions
A-IQOLS scores are sensitive to sample differences and are correlated with other asthma outcome measures. Changes in asthma control are significantly associated with changes in A-IQOLS scores, 2 providing grounds for optimism regarding its suitability as an outcome measure in clinical research and regarding the suitability of the IQOLS approach more generally for assessing the patient-perceived negative effect of other medical conditions. However, A-IQOLS sensitivity to experimental group differences has not yet been directly evaluated.
The present study populations do not exhaust the demographic or clinical diversity of patients in which the A-IQOLS or any measure using the A-IQOLS template might be used. The basic IQOLS stem question, dimension descriptions, and response scale already have been translated into many languages and national variants of those languages for an international clinical trial in another respiratory disease. Simply inserting the relevant translations of the word asthma into these language versions will yield a corresponding translation of the A-IQOLS. Further information is available from the corresponding author.
Conclusions
The A-IQOLS measures the patient-perceived effect of asthma and its treatment on the patient's life. The dimensions of life underlying the A-IQOLS are important across adults of both sexes; all age groups; white, African American, and Asian ancestry; Hispanics and non-Hispanics; and all levels of education, but their importance varies greatly between subjects. A-IQOLS scores are significantly associated with standardized measures of symptom and disease control in all of these demographic subgroups and can be recommended for use in those groups. A-IQOLS scores discriminate between asthmatic patients with different levels of disease control and severity at least as well as functional status or asthma-specific QoL measures but yield unique information.
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*ASUI and Juniper Symptom Z-scores of AQOLIS group were shifted by +0.02 in order to visually discriminate data points. † On the Marks AQLQ and A-IQOLS, higher scores indicate worse asthma status/effect. Scores on both measures have been inverted in this figure to be consistent with the orientation of the other measures. Personal Importance àTwo BTR participants were missing education information. §Differences in A-IQOLS mean score by level of education and treatment step remained statistically significant after controlling for ACT score (P 5 .008 and P < .0001, respectively). Pooled sample size, n 5 590; 1 AQOLIS, 2 DASH study, and 6 BTR participants were missing a baseline PPFEV 1 value. àPearson correlation between the ASUI and the Mini-AQLQ symptom score in the AQOLIS sample was 0.81. Linear regression was used to impute ASUI scores from Juniper symptom scores in the DASH study and BTR samples and to impute Mini-AQLQ symptom scores in the LASST sample and CPAP study samples from their ASUI scores.
Quality of Life Dimension
§One CPAP study participant is missing the Marks AQLQ score. kPearson correlation between the Mini-AQLQ total score and the Marks AQLQ score in the AQOLIS sample was 20.80. Linear regression was used to impute Marks AQLQ scores for DASH study and BTR samples from their Juniper total scores and to impute Juniper total scores in the LASST and CPAP studies from their Marks scores. {AQOLIS and the DASH study used the Mini-AQLQ; BTR used the standardized Juniper AQLQ.
